Cerberus exec

Cerberus exec

TOKYO, Japan - Louis Foster, senior managing director of U.S. private equity fund Cerberus Capital Management LP, speaks during a press conference in Tokyo on June 17, 2013. Foster said the fund, the largest shareholder of Seibu Holdings Inc., is not eyeing a proxy fight to secure votes for its proposals at the Japanese company's shareholders meeting on June 25, 2013.

  • Product Code
  • ILEA001183560
  • Registered date
  • 2013/6/17 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2013 Kyodo News
  • Media size
  • 1370 × 1857 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 381.45(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Suntory Whisky “Bimi Quality” press conference

    Suntory Whisky “Bimi Quality” press conference

    Suntory Whiskey held a press conference for Whiskey Day. Photo from left to right: Masanori Morimoto, Managing Executive Officer and General Manager of Spirits Division, and Yoshio Myojo, General Manager of Blender Office.=October 8,2024,Tokyo
      KDDI to deploy drones to aid disaster relief

      KDDI to deploy drones to aid disaster relief

      A drone flies in the dark during a demonstration at a KDDI Corp. press conference in Tokyo on May 13, 2024. In partnership with U.S. drone company Skydio Inc., the Japanese telecom company plans to deploy such drones, equipped with cameras and sensors, at 1,000 locations across Japan in order to respond quickly to earthquakes and other natural disasters.
        KDDI to deploy drones to aid disaster relief

        KDDI to deploy drones to aid disaster relief

        A drone flies in the dark during a demonstration at a KDDI Corp. press conference in Tokyo on May 13, 2024. In partnership with U.S. drone company Skydio Inc., the Japanese telecom company plans to deploy such drones, equipped with cameras and sensors, at 1,000 locations across Japan in order to respond quickly to earthquakes and other natural disasters.
          Japan's Cosmo investors OK anti-takeover step

          Japan's Cosmo investors OK anti-takeover step

          A man heads to the venue of Japanese oil wholesaler Cosmo Energy Holdings Co.'s annual shareholders meeting in Tokyo on June 22, 2023. The firm's shareholders approved a company proposal to implement anti-takeover measures in the face of a large-scale share purchase by an activist shareholder group.
            Japan's Cosmo investors OK anti-takeover step

            Japan's Cosmo investors OK anti-takeover step

            People head to the venue of Japanese oil wholesaler Cosmo Energy Holdings Co.'s annual shareholders meeting in Tokyo on June 22, 2023. The firm's shareholders approved a company proposal to implement anti-takeover measures in the face of a large-scale share purchase by an activist shareholder group.
              U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

              U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

              Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                    Japan Display to receive capital injection

                    Japan Display to receive capital injection

                    Japan Display Inc. CEO Minoru Kikuoka attends a press conference in Tokyo on Dec. 12, 2019, at which he announced the company agreed with private fund Ichigo Asset Management Ltd. to receive a capital injection of up to 90 billion yen ($830 million). (Kyodo) ==Kyodo
                      JDI President Kikuoka at a press conference

                      JDI President Kikuoka at a press conference

                      Japan Display Inc. (JDI) has finalized a new fundraising framework totaling over 100 billion yen. In addition to raising 80-90 billion yen from Ichigo Asset Group, an independent investment fund, JDI will also sell some of its facilities at its Hakusan plant (Hakusan, Ishikawa Prefecture) to Apple Inc. On April 12, JDI announced that it had reached a basic agreement with Ichigo Trust to raise up to 90 billion yen from Ichigo. Minoru Kikuoka, president of JDI, explained the purpose of the framework at a press conference on January 12, saying, "We will sell assets in order to enhance our capital and at the same time minimize the impact on existing shareholders through dilution. He explained the purpose of the framework. Wistron, a major Taiwanese electronics manufacturing service (EMS) company, also intends to invest 50 million dollars (about 5.4 billion yen) in JDI. December 12, 2019, Tokyo, Japan; Credit: Nikkan Kogyo Shimbun / Kyodo News Images